Source
From SEC EDGAR
156 releases originally issued via SEC EDGAR. The issuing organizations are responsible for their content.
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
•Announced updated clinical data in more than 80 patients from the ongoing PiNACLE pivotal trial in patients with 3L+ R/R LBCL and from the Phase 1/2…
GLOBAL NET LEASE REPORTS THIRD QUARTER 2026 RESULTS
–Closed $535 Million Accretive Modiv Industrial Acquisition and Fully Integrated Acquired Portfolio, Achieving Anticipated G&A Synergies With No…
Palmer Square Capital BDC Inc. Announces Third Quarter 2026 Financial Results
Declares Fourth Quarter 2026 Base Dividend of $0.36 Per Share with Supplemental Dividend
Sunrun Reports Third Quarter 2026 Financial Results
Robust sales growth continued in our direct business
Myriad Genetics Reports Third Quarter 2026 Financial Results;
Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution
Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well…
OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results
Conference Call to Begin Today at 4:30 p.m. ET
HCI Group Reports Third Quarter 2026 Results
Third Quarter Pre-Tax Income of $116 million
agilon health Reports Third Quarter 2026 Results
Revenue increased 6% to $1.52 billion Compared to the Same Period in the Prior Year
Motorola Solutions Reports Third-Quarter 2026 Financial Results
Company raises full-year revenue and earnings outlook again and increases full-year cash flow expectations
Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right…
CF Industries Holdings, Inc.
CF Industries Holdings, Inc. Reports First Nine Months 2026 Net Earnings of $1.78 Billion, Adjusted EBITDA of $3.01 Billion